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Introduction
The integrase inhibitor dolutegravir (within a ixed-dose 
combination of tenofovir disoproxil fumarate [tenofovir], 
lamivudine, and dolutegravir) is being considered for use 
(and, increasingly, used) in several countries in 
sub-Saharan Africa instead of efavirenz (in the form of 
tenofovir, lamivudine, and efavirenz) for people initiating 
antiretroviral therapy (ART) because of superior 
tolerability and a lower risk of resistance emergence.1,2 
However, there have been concerns over an increased 
risk of neural tube defects in babies conceived by women 
while taking dolutegravir.3 An approach to inform 
decision making is to quantify the risks and beneits of 
treatment policies through modelling to understand 
whether the beneits outweigh the risks. We previously 
reported such an analysis in the context of a policy of 
using dolutegravir in new ART initiators and switching 
from efavirenz to dolutegravir in people already on ART.4 
However, this previous evaluation did not consider the 
speciic question addressed in a 2019 WHO Antiretroviral 
Guidelines update,5 which was restricted to the choice of 
dolutegravir or efavirenz in new ART initiators. 
Furthermore, since our previous evaluation, additional 
data have emerged to inform risks and beneits.2,3,6 
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Summary
Background The integrase inhibitor dolutegravir is being considered in several countries in sub-Saharan Africa 
instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolerability and a lower risk 
of resistance emergence. WHO requested updated modelling results for its 2019 Antiretroviral Guidelines update, 
which was restricted to the choice of dolutegravir or efavirenz in new ART initiators. In response to this request, we 
modelled the risks and beneits of alternative policies for initial irst-line ART regimens.
Methods We updated an existing individual-based model of HIV transmission and progression in adults to consider 
information on the risk of neural tube defects in women taking dolutegravir at time of conception, as well as the 
efects of dolutegravir on weight gain. The model accounted for drug resistance in determining viral suppression, 
with consequences for clinical outcomes and mother-to-child transmission. We sampled distributions of parameters 
to create various epidemic setting scenarios, which relected the diversity of epidemic and programmatic situations in 
sub-Saharan Africa. For each setting scenario, we considered the situation in 2018 and compared ART initiation 
policies of an efavirenz-based regimen in women intending pregnancy, and a dolutegravir-based regimen in others, 
and a dolutegravir-based regimen, including in women intending pregnancy. We considered predicted outcomes over 
a 20-year period from 2019 to 2039, used a 3% discount rate, and a cost-efectiveness threshold of US$500 per 
disability-adjusted life-year (DALY) averted.
Findings Considering updated information on risks and beneits, a policy of ART initiation with a dolutegravir-based 
regimen rather than an efavirenz-based regimen, including in women intending pregnancy, is predicted to bring 
population health beneits (10 990 DALYs averted per year) and to be cost-saving (by $2·9 million per year), leading to 
a reduction in the overall population burden of disease of 16 735 net DALYs per year for a country with an adult 
population size of 10 million. The policy involving ART initiation with a dolutegravir-based regimen in women 
intending pregnancy was cost-efective in 87% of our setting scenarios and this inding was robust in various 
sensitivity analyses, including around the potential negative efects of weight gain.
Interpretation In the context of a range of modelled setting scenarios in sub-Saharan Africa, we found that a policy of 
ART initiation with a dolutegravir-based regimen, including in women intending pregnancy, was predicted to bring 
population health beneits and be cost-efective, supporting WHO’s strong recommendation for dolutegravir 
as a preferred drug for ART initiators.
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Updated data are available from the Tsepamo birth 
outcomes surveillance study in Botswana of neural tube 
defect risks with dolutegravir.3 Additionally, the 
NAMSAL2 and ADVANCE6 randomised trials have been 
fully published, which compared dolutegravir-based and 
efavirenz-based initial irst-line ART in Africa.
The ADVANCE trial6 gave rise to concern over 
substantial weight gain possibly caused by dolutegravir, 
particularly in women, for whom there was an average 
gain in weight of over 6 kg in 48 weeks in one dolutegravir 
group. In this study, we provide updated modelling 
results considering these updated data. These analyses 
were produced in response to a request from WHO to 
update modelling results for the 2019 Antiretroviral 
Guidelines revision.5
Methods
Modelling approach
We have previously described our model and how it was 
applied to consider risks and beneits of dolutegravir 
introduction.4 Briely, the model is an individual-based 
model of sexual behaviour, transmission, and progression 
of HIV and the efect of ART in an adult population, with 
updates every 3 months. We sampled from distributions 
of parameters relating to, for example, rates of HIV 
testing, linkage and retention, ART adherence, resis t-
ance, interruption, extent of implementation of viral load 
monitoring, and rate of switching to second-line therapy 
after detected virological failure to create various epidemic 
setting scenarios, which relect the diversity of epidemic 
and programmatic situations in sub-Saharan Africa 
(table 1). Values for several parameters relating to the 
potency of speciic drugs, their toxicity proile, and the 
efects of toxicity on ART interruption, as well as drug 
resistance risk, the previous distribution of which relects 
uncertainty over the values, were also varied across these 
setting scenarios. Descriptions and previous distributions 
of parameters are shown in the appendix (p 31).
Modelling of drug activity and resistance
The ongoing efect of an ART regimen in a modelled 
person depends on current adherence and the current 
level of activity of the overall regimen, dependent on the 
potency (activity against HIV when resistance is not 
present) of each drug and whether resistance mutations 
relevant to that drug are present (appendix p 5). Based on 
the results from the ADVANCE6 and NAMSAL2 trials, we 
assumed that dolutegravir and efavirenz have equal 
potency (1·5; ie, when no resistance mutations are 
present they contribute 1·5 active drugs to the overall 
drug activity; all nucleoside analogue reverse-transcrip t-
ase inhibitors have potency 1). Drug resistance has a low 
chance of arising in any regimen with three or more 
active drugs when adherence is high, but the risk 
becomes more substantial with lower current regimen 
activity and with low-to-moderate adherence. We 
See Online for appendix
Research in context
Evidence before this study
The integrase inhibitor dolutegravir has high potency and 
barrier to resistance, good tolerability, and low cost and has 
been adopted for use as a first-line antiretroviral therapy (ART) 
in some sub-Saharan African countries. In light of early data 
suggesting a possible risk of neural tube defects in babies of 
women taking dolutegravir at conception, in 2018, WHO made 
a conditional recommendation for dolutegravir as a preferred 
drug in ART initiators, with a note of caution when the drug 
was given to women of childbearing potential. Additionally, 
further data from randomised trials have emerged comparing 
dolutegravir-based first-line ART with efavirenz-based first line 
ART, including a new concern over weight gain with 
dolutegravir. Our team and another group previously modelled 
the risks and benefits of dolutegravir-based regimens. We 
searched Web of Science on May 15, 2019, and again on 
Nov 1, 2019, with no language restrictions, with the search 
terms “dolutegravir” AND “model*” and found no further 
published studies in any language that specifically modelled the 
risks and benefits of dolutegravir-based regimens for ART 
initiators.
Added value of this study
We modelled the balance of risks and benefits of ART initiation 
policies of an efavirenz-based regimen in women intending 
pregnancy and a dolutegravir-based regimen in others compared 
with a dolutegravir-based regimen in all ART starters, including 
in women intending pregnancy. We considered data published 
since our previous modelling of risks and benefits of 
dolutegravir-based regimens, including updated information on 
the possible small risk of neural tube defects in babies of women 
taking dolutegravir at conception and weight gain. We found 
that a policy of ART initiation with a dolutegravir-based regimen, 
including in women intending pregnancy, was predicted to bring 
net population health benefits and to be cost saving. Such a 
policy was cost-effective in 87% of our setting scenarios and this 
finding was robust in various sensitivity analyses.
Implications of all the available evidence
As shown by our analysis and a separate analysis by another 
modelling group, and in light of all evidence currently available, 
initiation of antiretroviral therapy with a dolutegravir-based 
regimen, including in women intending pregnancy, is predicted 
to bring population health benefits and be cost-effective. In 
July 2019, WHO updated its guidelines to make a strong 
recommendation for dolutegravir as a preferred drug in ART 
initiators for all HIV-positive adults. No recommendation 
currently exists for people who are already on a first-line 
efavirenz-based regimen as to whether a switch should be 
made to a dolutegravir-based regimen.
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maintained our previous assumption that the rate of 
resistance to dolutegravir (for a given level of regimen 
activity and adherence) is 13 times lower than efavirenz, 
with a small proportion of setting scenarios with a four 
times lower risk only.4 Although the relative rate of 
resistance between drugs was unchanged from our 
previous work, given the high levels of viral suppression 
in the ADVANCE trial,6 we considered that the absolute 
rate of resistance to all drugs could be lower than we 
originally assumed and thus included a higher proportion 
of setting scenarios with half the base rate of resistance 
(50% rate of resistance compared with base case in 54% 
of setting scenarios). Our base assumption was that 
mutations Gly190Ala and Tyr181Cys reduce efavirenz 
activity by 75% and Lys103Asn reduces efavirenz activity 
by 100%. The above assumption holds for 76% of setting 
scenarios—for 20% of setting scenarios activity level is 
reduced by 50% if any of the mutations are present and 
for 4% of setting scenarios activity level is reduced by 
75%. With these assumptions, the mean odds ratio (OR) 
for viral load greater than 1000 copies per mL at 1 year 
from start of ART associated with pre-treatment 
non-nucleoside reverse transcriptase inhibitor drug 
resistance is 3·3 (1·75 in a sensitivity analysis).
Modelling of mother-to-child transmission and neural 
tube defects 
Our assumption of risk of mother-to-child transmission 
was unchanged from our previous analysis.4 We assumed 
that for each subsequent year of the time horizon, 
0·1 disability-adjusted life-years (DALYs) are experienced 
for an HIV-positive baby and a cost of US$160 incurred 
as a conservative estimate of ART care costs, unchanged 
from our previous publication.4 We updated the risk of 
neural tube defects in pregnant women due to 
dolutegravir to 0·22% (0·30% minus the 0·08% 
background rate, compared with 0·58% previously).3,4 As 
before, for a woman having a baby with a neural tube 
defect an extra DALY was assumed to be incurred for 
each subsequent year of the time horizon due to loss of 
years of the child’s life.4 No additional costs were 
assumed. The presence of current toxicity increased the 
risk of drug interruption and increased weight was 
considered an additional toxic efect of dolutegravir.
Median (range)4 Examples of observed data*
HIV prevalence (age 15–49 years) 13% (2·3–28·0) Zimbabwe 2016 13%; Tanzania 2017 5%; Uganda 2017 6%; Lesotho 2017 24%; 
eSwatini 2017 27%; Malawi 2016 10%; Namibia 2017 12%; Zambia 2016 11%; 
Cameroon 2017 3·4%; Côte d’Ivoire 2017–18 2·5%
HIV incidence (age 15–49 years per 
100 person-years)
0·90 (0·10–2·86) Malawi 2016 0·37; Zambia 2016 0·66; Zimbabwe 2016 0·45; Lesotho 2017 1·55; 
Namibia 2016 0·40; Swaziland 2017 1·48, Tanzania 2017 0·27; Cameroon 2017 0·27
Proportion of HIV-positive people 
diagnosed
84% (50–97); 76% men, 
90% women)
Malawi 2016 77%; Zambia 2016 67%; Zimbabwe 2016 74%; Namibia 2017 86%; 
Tanzania 2017 52%; Ethiopia 2018 72%; Côte d’Ivoire 2017–18 37%; 
Cameroon 2017 47%
Proportion of diagnosed HIV-positive 
people on ART
88% (68–99) Lesotho 2016–17 92%; South Africa 2017 71%; eSwatini 2016–17 87%; 
Namibia 2017 96%; Zambia 2016 87%; Tanzania 2016–17 94%; Ethiopia 99%; 
Malawi 2016 91%; Uganda 2016–17 90%; Cameroon 2017 91%; Zimbabwe 2016 87%; 
Côte d’Ivoire 2017–18 88%; Cameroon 2017 91%
Proportion of all HIV-positive people 
with viral load <1000 copies per mL
60% (36–82) Zambia 2016 60%; Malawi 2016 68%; Zimbabwe 2016 60%; Swaziland 2017 73%; 
Lesotho 2017 68%; Tanzania 2017 52%; Uganda 2017 60%; Namibia 2017 77%; 
Ethiopia 2018 70%; Côte d’Ivoire 2017–18 40%; Cameroon 2017 47%
Proportion of ART-experienced people 
who have started second-line ART
4% (0·6–31·0) Malawi ~3% (Malawi Ministry of Health Quarterly Reports)
Proportion of people on ART with viral 
load <1000 copies per mL
88% (72–97); 85% men, 
89% women
Zambia 2016 men 88%, women 90%; Malawi 2016 men 90%, women 92%; 
Zimbabwe 2016 men 84%, women 88%; Namibia 2017 men 92%, women 90%; 
Tanzania 2017 men 89%, women 83%; Ethiopia 2018 men 95%, women 87%; 
Côte d’Ivoire 2017–18 76%; Cameroon 2017 80%
Proportion of people on ART with CD4 
<500 cells per µL (in 2016)
44% (30–70) eSwatini 40% 2016–17; Malawi 52% 2016; Tanzania 2017–18 55%; Zambia 2016 59%
Proportions of ART-naive ART 
initiators with non-nucleoside reverse 
transcriptase inhibitor resistance
8% (1–30) Angola 2012 14%; Botswana 2016 8%; South Africa 2017 14%; Zimbabwe 2015 10%; 
Namibia 9%; Uganda 2016 16%; Cameroon 8% (HIV drug resistance report 20177)
Mother-to-child transmission rate 9% (3–25) (including breastfeeding period) Botswana 5%, South Africa 5%; Namibia 6%; 
Uganda 8%; Zimbabwe 7%; Malawi 9%; Tanzania 12%; Ethiopia 21%; Côte d’Ivoire 16%; 
Cameroon 15% (UNAIDS 20198)
Proportion of women aged 
15–65 years giving birth per year
12% (5–19) South Africa 6%; Botswana 7%; Namibia 10%; Malawi 15%; Zimbabwe 12%; 
Uganda 18%; Tanzania 16%; Ethiopia 12%; Côte d’Ivoire 15%, Cameroon 14% 
(2019 Revision of World Population Prospects9)
ART=antiretroviral therapy. *All data from Population Health Impact Assessment surveys, Human Sciences Research Council South Africa National HIV survey,10 or Botswana 
Combination Prevention Project (2013–15),11 unless otherwise stated.
Table 1: Setting scenarios in 2018 (n=1000)
For more on Population Health 
Impact Assessment surveys see 
https://phia.icap.columbia.edu/
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Modelling potential effects of weight gain due to 
dolutegravir
We included efects on morbidity and mortality because of 
the efects of weight on conditions such as diabetes, as well 
as possible efects of potential increases in bodyweight on 
babies of pregnant women. For mortality, we based our 
assumptions on data concerning the observed relationship 
between body-mass index (BMI) and all-cause mortality, 
both in HIV-positive people and the general population,12,13 
as suggested could be possible, based on a pooled analysis 
of BMI and cardiometabolic multimorbidity.14 We assumed 
that a proportion (50% or 75%15,16) of people have a BMI 
greater than 23 kg/m² at dolutegravir initiation, such that a 
rise in the order of that seen in the ADVANCE trial6 for 
people on tenofovir, lamivudine, and dolutegravir might 
be clinically signiicant.3 We sampled a range of values for 
the excess risk of non-HIV mortality from 1·00 times to 
1·25 times (appendix p 36). Additionally, many non-AIDS 
deaths will be associated with several years of previous 
morbidity, which reduces health (incurs DALYs) and incurs 
costs to the health-care system. We accounted for these by 
assuming a one DALY increment for a person who dies 
from a non-AIDS cause (not withstanding discounting), 
relecting 10 years of living with a disability weight of 0·1 
ART initiation with tenofovir, 
lamivudine, and efavirenz in women 
intending pregnancy*
ART initiation with tenofovir, 
lamivudine, and dolutegravir in women 
intending pregnancy*
Proportion of women intending pregnancy on ART who are on†
Dolutegravir 0% 48%, 48% (48 to 48; 37 to 57)
Efavirenz 92% 46%, –46% (–46 to –46; –56 to –33)
Atazanavir‡ 8% 6%, –2% (–2 to –2; –7 to 0)
Tenofovir 92% 94%, 2% (2 to 2; 0 to 7)
Lamivudine 100% 100%, 0% (0 to 0; 0 to 0)
Zidovudine 8% 6%, –2% (–2 to –2; –7 to 0)
Proportion of women intending pregnancy with viral load 
<1000 copies per mL 12 months from ART initiation†
74% 80%, 6% (6 to 6; 0 to 12)
Proportion of women intending pregnancy on ART with viral 
load <1000 copies per mL 12 months from ART initiation†
82% 88%, 6% (6 to 6; 1 to 13)
Proportion of women intending pregnancy on ART with viral 
load <1000 copies per mL†
84% 89%, 5% (5 to 5; 1 to 10)
In women intending pregnancy on ART at 12 months from 
start of ART, change in CD4 cell count per µL†
132 151, 20 (19 to 20; 1 to 43)
Proportion of all HIV-positive people with:†
Efavirenz resistance 23% 19%, –4% (–4 to –4; –9 to –1)
Dolutegravir resistance 1% 2%, 1% (1 to 1; 0 to 3)
Death rate in women intending pregnancy on ART (per 
100 person-years)†
1·78 1·42, –0·36 (–0·38 to –0·034; –1·00 to –0·01)
HIV-related 1·03 0·65, –0·38 (–0·40 to –0·036; –1·02 to –0·05)
Non-HIV-related 0·76 0·78, 0·02 (0·02 to 0·02; 0·07 to 0·12)
Outcomes for babies—annual number of cases of:†
Neural tube defects 1 73, 72 (69 to 74; 15 to 156)
Mother-to-child transmission 9650 8150, –1500 (–1400 to –1600; –4450 to 0)
Excess stillbirths or neonatal death due to dolutegravir-
induced increase in BMI
1 43, 42 (40 to 45; 0 to 124)
Mean total DALYs averted per year compared with tenofovir, 
lamivudine, and efavirenz (DALYs in adults, DALYs 
due to neural tube defects and other dolutegravir-induced 
obesity-related adverse neonatal events)
·· 10 990 (10 248, 11 732; –7075 to 31 840)
Breakdown of mean total DALYs averted per year compared with tenofovir, lamivudine, and efavirenz
Before accounting for neural tube defects, prevention of 
mother-to-child transmission, and morbidity effects of 
weight gain
·· 10 970
Neural tube defects ·· –270
Mother-to-child transmission ·· 510
Excess risk of stillbirth or neonatal death 
due to dolutegravir-induced increase in BMI
·· –170
Pre-death morbidity due to weight gain ·· –40
(Table 2 continues on next page)
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(eg, the same as the weight for diabetic foot; moderate 
angina or moderate heart failure has a disability weight of 
0·0717). Regarding the cost of management of these 
conditions, we have a one-of  mean cost of the years of 
health care for morbidity for all non-AIDS deaths. We 
assumed a value of $1000, informed by health-care budgets 
for non-communicable diseases in sub-Saharan Africa.18,19 
There is also a potential excess of neonatal death caused by 
dolutegravir-induced weight gain. The overall risk of 
neonatal death for women of normal bodyweight is around 
1·6%.20 The rate ratio for neonatal death per unit of higher 
BMI for women with BMI above 23 kg/m² is around 1·05, 
so the absolute excess risk due to a 2·5 kg increase in 
weight is 0·08% ([1·05 – 1] × 1·6%). As there is also a 
potential excess risk of stillbirth, for which the absolute 
risk is similar, the overall risk of stillbirth or neonatal death 
is around 0·16%. We sampled the risk of stillbirth or 
neonatal death from 0·05% to 0·30%.
Policies compared, DALYs, and net DALYs
For each setting scenario, we considered the situation in 
2018 and compared ART initiation policies of initiating 
ART with tenofovir, lamivudine, and efavirenz in women 
intending pregnancy, and initiating ART with tenofovir, 
lamivudine, and dolutegravir in others and initiating 
ART with tenofovir, lamivudine, and dolutegravir, 
including in women intending pregnancy. We 
considered predicted outcomes over a 20-year period 
from 2019 to 2039. We calculated DALYs for the entire 
adult population, assuming that a woman having a child 
with a neural tube defect incurs an extra DALY per year 
for the remainder of the time horizon and also 
accounting for mother-to-child transmission. Unless 
stated otherwise, absolute numbers of health-related 
events, costs, and DALYs are relevant for a country of 
population size of around 10 million adults in 2018. As 
in our previous study,4 cost-efectiveness analyses were 
done from a health-care perspective, costs and health 
outcomes were both discounted to present US$ values at 
3% per annum, and a cost-efectiveness threshold of 
$500 per DALY averted was used. We used this threshold 
to calculate net DALYs averted (net DALYs averted=DALYs 
averted + [diference in costs ÷ cost-efectiveness thres h-
old]). Net DALYs accounted for the health consequences 
of the diference in costs as well as the diference in 
health and relected the efect of a policy on the overall 
population burden of disease. Costs and disability 
weights are shown in the appendix (p 38).
ART initiation with tenofovir, 
lamivudine, and efavirenz in women 
intending pregnancy*
ART initiation with tenofovir, 
lamivudine, and dolutegravir in women 
intending pregnancy*
(Continued from previous page)
Mean cost over 3-month periods from 2019 to 2039 (millions of US$, discounted at 3% per year)§
Total 195·7 192·9 (difference –2·9)
HIV tests 10·8 10·7
Efavirenz 18·2 13·0
Dolutegravir 4·7 10·2
Lamivudine 19·8 19·9
Tenofovir 27·4 27·9
Zidovudine 4·4 3·9
Atazanavir 13·1 11·4
Clinic visits (non-ART programme costs) 55·0 55·1
Treatment or care for WHO stage 3 or 4 events 12·4 11·5
Viral load tests 7·4 7·3
Treatment for children because of mother-to-child 
transmission
6·9 6·3
Non-AIDS pre-death morbidity 14·4 14·5
CD4 counts 0·5 0·5
Adherence counselling 0·2 0·1
Cost in staff time of switching to second-line ART 0·1 0·1
Net DALYs averted per year ·· 16 735
ART=antiretroviral therapy. BMI=body-mass index. DALY=disability-adjusted life-year. *ART initiated in men and women not wanting (more) children is tenofovir, 
lamivudine, and dolutegravir. †Data in the first column are the mean over 3-month periods from 2019 to 2039 for each policy. Data in the second column are the mean, 
mean absolute difference (95% CI; 90% range reflecting variation across setting scenarios) compared with the policy of first-line tenofovir, lamivudine, and efavirenz in 
women intending pregnancy. ‡We assume atazanavir is used as the protease inhibitor in second-line ART. §Cost breakdown by regimen policy (for all adults in context of a 
population of 10 million adults). Tenofovir, lamivudine, and dolutegravir and tenofovir, lamivudine, and efavirenz are assumed to cost $75 per year, atazanavir $265 per year 
(Global Fund procurement list of drug costs, July 201821). Viral load test costs reflect that in some setting scenarios viral load testing is minimally implemented—the total cost 
is double this mean cost if fully implemented.
Table 2: Predicted effects of policy options over 20 years
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Role of the funding source
The funder of the study had no role in study design, 
modelling approach, data interpretation, or writing of the 
report. The corresponding author had full access to all 
model programs and outputs in the study and had inal 
responsibility for the decision to submit for publication.
Results
Our model predicted outcomes over 20 years for the 
two policies (tables 2 and 3). The mean proportion of 
women with viral suppression 1 year after the start 
of ART was around 6% higher for the policy of ART 
initiation with tenofovir, lamivudine, and dolutegravir 
in women intending pregnancy compared with the 
policy of ART initiation with tenofovir, lamivudine, and 
efavirenz in women intending pregnancy, with a 5% 
diference in the overall proportion of women on ART 
with viral suppression (table 2). There was also a slightly 
higher CD4 count rise 1 year from the start of ART with 
the policy of tenofovir, lamivudine, and dolutegravir in 
women intending pregnancy (table 2). These diferences 
led to a lower HIV-related death rate for the policy of 
tenofovir, lamivudine, and dolutegravir in women 
intending pregnancy (table 2). The non-HIV-related 
death rate was slightly higher for the policy of tenofovir, 
lamivudine, and dolutegravir in women intending 
pregnancy because of the efect of weight gain (table 2). 
Considering outcomes for babies, the higher number 
of neural tube defects and stillbirths and neonatal 
deaths associated with higher weight in mothers was 
substantially outweighed by the lower number of 
children born with HIV with the policy of tenofovir, 
lamivudine, and dolutegravir in women intending 
pregnancy (table 2).
Considering the whole adult population, more DALYs 
are averted with the policy of ART initiation with 
tenofovir, lamivudine, and dolutegravir in women 
intending pregnancy compared with the policy of 
tenofovir, lamivudine, and efavirenz. Overall costs were 
slightly lower with the policy of ART initiation with 
tenofovir, lamivudine, and dolutegravir in women 
intending pregnancy compared with the policy of ART 
initiation with tenofovir, lamivudine, and efavirenz in 
women intending pregnancy, driven mainly by lower 
use of the second-line drugs atazanavir and zidovudine 
and lower costs of care for HIV-related conditions 
(table 2). Net DALYs averted per year show a similar 
pattern to DALYs averted but since costs are averted 
Tenofovir, lamivudine, and 
dolutegravir brings direct health 
benefit (ie, DALYs averted)
Tenofovir, lamivudine, and 
dolutegravir is cost-effective 
(ie, net DALYs are averted)
Overall 83% 87%
Sensitivity analyses—restricted to setting scenarios for which:
Proportion of ART-naive ART initiators with non-nucleoside reverse transcriptase 
inhibitor resistance in 2018 is in the range 10–30%
89% 94%
Proportion of ART-naive ART initiators with non-nucleoside reverse transcriptase 
inhibitor resistance in 2018 <5%
79% 82%
HIV prevalence 10–28% in 2018 86% 91%
Proportion of people on ART with viral load <1000 copies per mL 90–97% in 2018 71% 77%
Proportion of people on ART with viral load <1000 copies per mL 72–85% in 2018 93% 95%
Viral load monitoring and switching to second-line ART operating well* 75% 87%
Viral load monitoring and switching to second-line ART operating poorly or not 
at all†
89% 87%
16–19% of women giving birth per year 78% 82%
5–12% of women giving birth per year 85% 89%
1·25 times increased risk of non-HIV death due to weight gain 76% 85%
≤1·05 times increased risk of non-HIV death due to weight gain 85% 88%
Absolute additional risk of stillbirth or neonatal death due to weight gain is 0·05% 82% 85%
Absolute additional risk of stillbirth or neonatal death due to weight gain is 0·30% 82% 84%
Risk of neural tube defects due to dolutegravir is 0·61% 82% 87%
Reduced impact of non-nucleoside reverse transcriptase inhibitor mutations on 
efavirenz activity‡
73% 78%
Halving of the risk of resistance mutations emerging for all drugs 82% 86%
ART=antiretroviral therapy. DALY=disability-adjusted life-year. *Viral load monitoring and switching to second-line ART operating poorly means the probability of each 
scheduled viral load test being done is 0·1 or 0; the probability per 3 months of a switch to second-line ART once failure criteria are met is 0 or 0·2. †Viral load monitoring 
and switching to second-line ART operating well means the probability of each scheduled viral load test being done is 0·85; the probability per 3 months of a switch 
to second-line ART once failure criteria are met is 0·5. ‡With this assumption, the mean odds ratio for viral load >1000 copies per mL at 1 year from the start of ART 
associated with pre-treatment on nucleoside reverse transcriptase inhibitor resistance is 1·75, compared with 3·3 for the overall result (appendix p 36).
Table 3: Proportion of setting scenarios in which tenofovir, lamivudine, and dolutegravir brings direct health benefit or is cost-effective, over 20 years
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with the policy of tenofovir, lamivudine, and dolutegravir 
in women intending pregnancy, the beneits are greater 
(table 2).
Overall, the policy of ART initiation with tenofovir, 
lamivudine, and dolutegravir in women intending 
pregnancy produced more health than the policy of ART 
initiation with tenofovir, lamivudine, and efavirenz in 
women intending pregnancy (DALYs were averted) in 
83% of setting scenarios and was cost-efective (net 
DALYs averted) in 87% of setting scenarios (table 3). 
In sensitivity analyses restricted to setting scenarios with 
particular characteristics, the policy of tenofovir, 
lamivudine, and dolutegravir in women intending 
pregnancy remained the most cost-efective in over 75% 
of setting scenarios (table 3). A corresponding multi-
variable model is shown in the appendix (p 2). We also did 
a sensitivity analysis to assess policies over a 50-year time 
horizon instead of the 20-year time horizon in our 
primary analyses. The proportion of setting scenarios in 
which tenofovir, lamivudine, and dolutegravir brought 
direct health beneit was 94% and the propor tion in which 
it was cost-efective was 98%.
Discussion
The results of this study add to our previous evaluation 
of the risks and beneits of adoption of dolutegravir 
within antiretroviral regimens.4 Considering data from 
the ADVANCE6 and NAMSAL2 trials and the Tsepamo 
study,3 we found that the policy of ART initiation with 
tenofovir, lamivudine, and dolutegravir in women 
intending pregnancy is predicted to lead to more health 
life years compared with the policy of ART initiation 
with tenofovir, lamivudine, and efavirenz in women 
intending pregnancy and is cost-efective. Because of the 
results of the ADVANCE6 and NAMSAL2 trials, we 
modiied our previous assumptions such that the 
potency of efavirenz and dolutegravir was taken as equal, 
when we previously considered that potency was likely 
to be higher for dolutegravir. We also accounted for 
a possible efect of weight gain due to dolutegravir on 
non-AIDS morbidity and mortality. Nevertheless, the 
policy of ART initiation with tenofovir, lamivudine, and 
dolutegravir in women intending pregnancy was more 
cost-efective in 87% of our setting scenarios and this 
result was robust across several sensitivity analyses in 
which our assumptions were varied within plausible 
bounds. The predicted health beneits of tenofovir, 
lamivudine, and dolutegravir are substantial—eg, the 
decreased death rate in women on ART of 0·36 per 
100 person-years could translate into over 1800 deaths in 
women per year for Zimbabwe. Our results are 
consistent with those of a modelling analysis from the 
CEPAC study.22 These results were presented for 
consideration by the WHO guidelines development 
group, which reviewed all the available evidence and 
made a strong recommendation for dolutegravir 
as a preferred drug in ART initiators.5
Studies have consistently shown that dolutegravir 
leads to lower rates of discontinuation than efavirenz.1,2,6 
In our analysis, the predicted health beneits of the 
policy of ART initiation with tenofovir, lamivudine, and 
dolutegravir in women intending pregnancy are mainly 
driven by the higher genetic barrier to resistance of 
dolutegravir compared with efavirenz, rather than this 
tolerability beneit. It is di cult to ascertain how the 
tolerability beneits of dolutegravir play out in the 
context of settings in which drug switching is not readily 
available because of interrupted procurement of 
efavirenz, and where the choice might be between 
continuing the current regimen or stopping ART 
altogether. Additionally, the likelihood of subsequent 
reinitiation of ART at some point after interruption 
should be considered, and we assume that, in a person 
who has interrupted ART, the subsequent development 
of an HIV-related condition (WHO stage 3 or stage 4) 
leads to an increased probability that they will resume 
therapy. If rates of stopping all ART are substantially 
greater for people on tenofovir, lamivudine, and 
efavirenz than on tenofovir, lamivudine, and dolutegravir, 
the beneits of tenofovir, lamivudine, and dolutegravir 
are likely to be greater than those we describe in this 
study. Side-efects of drugs, including weight gain, and 
their efect on ART use patterns should continue to be 
monitored carefully over the long term.
Our assumptions about the potential efects of weight 
gain on non-AIDS mortality include efects (1·25 times 
for the duration of time on dolutegravir) beyond what 
would be predicted on the basis of observed associations 
between BMI and mortality.12,13 We took a conservative 
approach because of uncertainty over consequence of 
dolutegravir-induced weight gain. We also considered 
that weight gain could lead to an increased risk of 
stillbirth or neonatal mortality in the babies of mothers 
on the drug, which might be particularly relevant given 
the larger weight gain observed in women.6 However, we 
emphasise that it is unclear whether any such efect 
exists and we included this efect to consider a worst case 
scenario for dolutegravir.
Modelling studies inevitably have the limitation that 
they are based on model design and assumptions, but 
our overall conclusion seems robust to alternative 
assumptions within plausible limits. Although our 
analysis has been widely considered and commented on, 
we cannot deinitively rule out that there are other 
alternative assumptions that we did not consider. 
Additionally, monitoring of new data on outcomes from 
use of dolutegravir as these emerge will be important, 
including on weight gain, resistance emergence, and 
neural tube defects, and updates to analyses should be 
made if required. Our evaluation pertains to people 
starting ART and does not address the question of risks 
and beneits of switching from tenofovir, lamivudine, 
and efavirenz to tenofovir, lamivudine, and dolutegravir 
in people already on ART.
Articles
8 www.thelancet.com/hiv   Published online February 5, 2020   https://doi.org/10.1016/S2352-3018(19)30400-X
In conclusion, in the context of a range of modelled 
setting scenarios in sub-Saharan Africa, we found that 
initiation of ART with a dolutegravir-based regimen was 
predicted to bring population health beneits and be 
cost-efective, supporting WHO’s strong recommen-
dation as a preferred drug in ART initiators, including 
women intending pregnancy.
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